Adela announced it raised $25.4 Million in an initial filing from an offering of $27 Million

Company

Location

About

Adela’s mission is to develop innovative and accessible technologies that harness biology and change the way we diagnose and treat disease. ‍ Adela’s genome-wide methylation enrichment technology was originally developed by Chief Scientific Officer Dr. Daniel De Carvalho, PhD, at University Health Network’s Princess Margaret Cancer Centre. ‍ Adela is initially planning to develop the technology for use across the entire cancer continuum—for detection, diagnosis and management of disease.